Shin Ahn1, Yoon-Seon Lee2, Jae-Lyun Lee3, Kyung Soo Lim1, Sung-Cheol Yoon4. 1. Department of Emergency Medicine, Cancer Emergency Room, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul, 138-736, Korea. 2. Department of Emergency Medicine, Cancer Emergency Room, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul, 138-736, Korea. ysdoc@amc.seoul.kr. 3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Division of Biostatistics, Center for Medical Research and Information, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: The objective of this study was to develop and validate a new prognostic model for febrile neutropenia (FN). METHODS: This study comprised 1001 episodes of FN: 718 for the derivation set and 283 for the validation set. Multivariate logistic regression analysis was performed with unfavorable outcome as the primary endpoint and bacteremia as the secondary endpoint. RESULTS: In the derivation set, risk factors for adverse outcomes comprised age ≥ 60 years (2 points), procalcitonin ≥ 0.5 ng/mL (5 points), ECOG performance score ≥ 2 (2 points), oral mucositis grade ≥ 3 (3 points), systolic blood pressure <90 mmHg (3 points), and respiratory rate ≥ 24 breaths/min (3 points). The model stratified patients into three severity classes, with adverse event rates of 6.0 % in class I (score ≤ 2), 27.3 % in class II (score 3-8), and 67.9 % in class III (score ≥ 9). Bacteremia was present in 1.1, 11.5, and 29.8 % of patients in class I, II, and III, respectively. The outcomes of the validation set were similar in each risk class. When the derivation and validation sets were integrated, unfavorable outcomes occurred in 5.9 % of the low-risk group classified by the new prognostic model and in 12.2 % classified by the Multinational Association for Supportive Care in Cancer (MASCC) risk index. CONCLUSIONS: With the new prognostic model, we can classify patients with FN into three classes of increasing adverse outcomes and bacteremia. Early discharge would be possible for class I patients, short-term observation could safely manage class II patients, and inpatient admission is warranted for class III patients.
BACKGROUND: The objective of this study was to develop and validate a new prognostic model for febrile neutropenia (FN). METHODS: This study comprised 1001 episodes of FN: 718 for the derivation set and 283 for the validation set. Multivariate logistic regression analysis was performed with unfavorable outcome as the primary endpoint and bacteremia as the secondary endpoint. RESULTS: In the derivation set, risk factors for adverse outcomes comprised age ≥ 60 years (2 points), procalcitonin ≥ 0.5 ng/mL (5 points), ECOG performance score ≥ 2 (2 points), oral mucositis grade ≥ 3 (3 points), systolic blood pressure <90 mmHg (3 points), and respiratory rate ≥ 24 breaths/min (3 points). The model stratified patients into three severity classes, with adverse event rates of 6.0 % in class I (score ≤ 2), 27.3 % in class II (score 3-8), and 67.9 % in class III (score ≥ 9). Bacteremia was present in 1.1, 11.5, and 29.8 % of patients in class I, II, and III, respectively. The outcomes of the validation set were similar in each risk class. When the derivation and validation sets were integrated, unfavorable outcomes occurred in 5.9 % of the low-risk group classified by the new prognostic model and in 12.2 % classified by the Multinational Association for Supportive Care in Cancer (MASCC) risk index. CONCLUSIONS: With the new prognostic model, we can classify patients with FN into three classes of increasing adverse outcomes and bacteremia. Early discharge would be possible for class I patients, short-term observation could safely manage class II patients, and inpatient admission is warranted for class III patients.
Authors: Lothar Hambach; Matthias Eder; Elke Dammann; Andreas Schrauder; Karl-Walter Sykora; Christian Dieterich; Philip Kirschner; Jürgen Novotny; Arnold Ganser; Bernd Hertenstein Journal: Haematologica Date: 2002-06 Impact factor: 9.941
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Timothy J Hodgetts; Gary Kenward; Ioannis G Vlachonikolis; Susan Payne; Nicolas Castle Journal: Resuscitation Date: 2002-08 Impact factor: 5.262
Authors: Carmen P Escalante; Mary Ann Weiser; Ellen Manzullo; Robert Benjamin; Edgardo Rivera; Tony Lam; Vi Ho; Rosalie Valdres; Eva Lu Lee; Noemi Badrina; Sally Fernandez; Yvette DeJesus; Kenneth Rolston Journal: Support Care Cancer Date: 2004-09 Impact factor: 3.603
Authors: Dong-Gun Lee; Sung-Han Kim; Soo Young Kim; Chung-Jong Kim; Wan Beom Park; Young Goo Song; Jung-Hyun Choi Journal: Korean J Intern Med Date: 2011-06-01 Impact factor: 3.165
Authors: Jihyoun Lee; Jong Eun Lee; Zisun Kim; Sun Wook Han; Sung Mo Hur; Sung Yong Kim; Min Hyuk Lee; Cheol Wan Lim Journal: Ann Surg Treat Res Date: 2018-04-30 Impact factor: 1.859
Authors: Jason J Bischof; Patrick J Sylvester; Jennifer A Frey; Julie A Stephens; Becca Hammond; Joshua Garmatter; Courtney Hebert; Jeffrey M Caterino Journal: J Am Coll Emerg Physicians Open Date: 2021-10-02
Authors: Paula Jiménez Fonseca; Alberto Carmona-Bayonas; Ignacio Matos García; Rosana Marcos; Eduardo Castañón; Maite Antonio; Carme Font; Mercè Biosca; Ana Blasco; Rebeca Lozano; Avinash Ramchandani; Carmen Beato; Eva Martínez de Castro; Javier Espinosa; Jerónimo Martínez-García; Ismael Ghanem; Jorge Hernando Cubero; Isabel Aragón Manrique; Francisco García Navalón; Elena Sevillano; Aránzazu Manzano; Juan Virizuela; Marcelo Garrido; Rebeca Mondéjar; María Ángeles Arcusa; Yaiza Bonilla; Quionia Pérez; Elena Gallardo; Maria Del Carmen Soriano; Mercè Cardona; Fernando Sánchez Lasheras; Juan Jesús Cruz; Francisco Ayala Journal: Br J Cancer Date: 2016-05-17 Impact factor: 7.640
Authors: Luis García de Guadiana-Romualdo; Pablo Cerezuela-Fuentes; Ignacio Español-Morales; Patricia Esteban-Torrella; Enrique Jiménez-Santos; Ana Hernando-Holgado; María Dolores Albaladejo-Otón Journal: Biochem Med (Zagreb) Date: 2018-12-15 Impact factor: 2.313